R&D Opportunity costs of gene therapies. Where do we go from her... Over 30 gene therapies have received regulatory approval.
News AscellaHealth recognised for rare disease funding programme AscellaHealth has been given an industry award for a financial solution designed to meet the affordability challenges of expensive treatments for rare and complex diseases
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
